Galectin Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 3.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 354.99M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin...